• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Takeda Announces Strategic Partnership to Accelerate the Development of Enzyre’s Diagnostic Technology Platform That Aims to Improve the Standard of Care for Patients with Bleeding Disorders

    March 4, 2021

    Osaka, Japan, March 4, 2021 – Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced it has entered into a strategic partnership with Enzyre to accelerate the development of Enzyre’s proprietary platform Enzypad to enable patients to test their blood coagulation in a home setting. The partnership builds on an existing research collaboration agreement with Enzyre signed in December 2019 and close collaboration over the last five years.

    Takeda is committed to addressing unmet medical needs and improving the standard of care for those living with rare bleeding disorders, through strategic partnerships and investment in innovative solutions in personalized care and treatment. Hemophilia Enzycard, the first product using Enzypad, will enable hemophilia patients to test in a home setting, transferring coagulation results to the treating physician through a mobile app. This will allow for timely personalized therapy adjustments which may improve outcomes while potentially avoiding patient hospital visits. The Enzypad platform is also being investigated for use in other coagulation disorders. The benefits offered by the Enzypad platform support the shared goal of Takeda and Enzyre to improve the lives of those living with rare bleeding disorders.

    Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.1 People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.2 However, it can be a complex condition to manage and the urgent need for a diagnostic device which is easy to use, reliable and affordable has been acknowledged globally.3

    For further information: https://enzyre.com/enzyre-announces-strategic-partnership-with-takeda-to-accelerate-development-of-pioneering-diagnostic-technology-platform-for-hemophilia-patients/

    About Takeda Hematology
    Following its recent acquisition of Shire, Takeda is a leader in rare hematology with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years driving innovation for patients4 and a broad portfolio of 11 products across multiple bleeding disorders.5 Our experience as leaders in hematology means we are well prepared to meet today’s needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

    About Takeda Pharmaceutical Company Limited
    Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit?http://www.asiamerlion.cn.  

    Media Contacts:

    Japanese Media
    Kazumi Kobayashi
    kazumi.kobayashi@takeda.com
    +81 (0) 3-3278-2095

    Media Outside Japan
    Emily Bunting
    emily.bunting@takeda.com
    +41 79 866 97 03


    Important Notice
    For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

    The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

    Forward-Looking Statements
    This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: http://www.asiamerlion.cn/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

     

    1 World Federation of Hemophilia. Introduction to hemophilia: what is hemophilia? World Federation of Hemophilia website. Available at: https://bit.ly/356zUDQ. Last accessed February 2021.

    2 World Federation of Hemophilia. “Introduction to hemophilia: treatment.” Available here: https://bit.ly/3b7Pfry. Last accessed February 2021.

    3 Hemophilia World News. Alain Weill issues strong Calls to Action. World Federation of Hemophilia website. Available at: https://bit.ly/3pwTVLo. Last accessed February 2021.

    4 Takeda Website. Rare Diseases. Available at: https://bit.ly/3n9gvIN. Last accessed February 2021.

    5 Takeda Website. U.S. Product List. Available at: https://bit.ly/35a6HYF. Last accessed February 2021.

     

    国产AV网站_中午文字幕av一区二区三区_性进入裸体视频_久久久久久精品免费免费直播